Document:

Exhibit

                                                                                                                                                                                                         
Exhibit 10.2

October 18, 2017

Axovant Sciences GmbH
Viaduktstrasse 8
4051 Basel 
Switzerland

		
	Attention:
	Marianne Romeo Dinsmore 

                                      Managing Director
                                       Axovant Sciences GmbH

Re: Non-Commercial Manufacturing Provisions of the Development,  Marketing and Supply Agreement, dated May 8, 2015, by and between Arena Pharmaceuticals GmbH and Axovant Sciences GmbH (as successor in interest to Axovant Sciences Ltd. and Roivant Sciences Ltd.)

Dear Mrs. Dinsmore:

Reference is hereby made to that certain Development, Marketing and Supply Agreement, dated May 8, 2015 (the "Supply Agreement"), by and between Arena Pharmaceuticals GmbH ("Arena") and Axovant Sciences GmbH (as successor in interest to Axovant Sciences Ltd. and Roivant Sciences Ltd.) ("Axovant"). Capitalized terms used in this letter agreement that are not otherwise defined shall have the meanings ascribed to such terms in the Supply Agreement.

WHEREAS, Section 2.3(c) of the Supply Agreement prohibits Axovant and its Affiliates from purchasing from any Third Party any Compound or Product, including, without limitation, for use in clinical trials or other development, and Section 9.1 of the Supply Agreement discusses the ownership of intellectual property; and

WHEREAS, the Parties desire to allow Axovant to engage Third Parties to manufacture Compound or Product exclusively for use in clinical trials or to conduct related development work, in each case pursuant to a Development Plan and in accordance with this letter agreement ("Manufacturing/Development Work");

NOW, THEREFORE, the Parties agree as follows:

		
	1.
	From time to time, Arena may permit Axovant to engage a Third Party to perform Manufacturing/Development Work. Nothing in this letter agreement modifies Section 2.2 of the Supply Agreement or permits Axovant to engage a Third Party to manufacture Compound or Product for any other purpose, including, without limitation, for Commercialization.

		
	2.
	If Axovant desires to engage a Third Party to perform Manufacturing/Development Work, Axovant shall so notify Arena. Such notice shall identify the Third Party and the Manufacturing/Development Work to be conducted by such Third Party. If Arena consents to Axovant seeking to engage a Third Party to perform the Manufacturing/Development Work, which consent shall be in Arena's sole discretion, then the Parties shall amend Appendix A hereto to list such Third Party and such Manufacturing/Development Work. Axovant shall not enter into any agreement with a Third Party relating to Manufacturing/Development Work (each, a "Third Party Manufacturing Agreement") without Arena's prior written approval, which approval shall be documented as described in Section 4 below.

		
	3.
	Each Third Party Manufacturing Agreement shall provide for the following:

		
	a.
	Upon Arena's election, the Third Party Manufacturing Agreement shall be immediately assignable by Axovant to Arena or its Affiliate (as designated by Arena), and it shall provide that any obligations accruing prior to the date of assignment shall remain the sole responsibility of Axovant.

		
	b.
	The Third Party must promptly notify Axovant in writing of the discovery, identification, conception, reduction to practice or other making of any Know-How or Patents by or on behalf of such Third Party in the course of or as a result of activities conducted under the Third Party Manufacturing Agreement.

		
	c.
	Know-How and Patents that (a) are reasonably necessary for the development, manufacture or Commercialization of Compound or Product, or (b) relate solely to, or are specifically tailored for use in, the manufacture of Compound or Product, shall be assigned to Axovant or, if Arena consents, licensed (with the right to sublicense) to Axovant.

		
	d.
	Compound and Product shall be delivered only to such location(s) and person(s) as instructed by Axovant.

		
	e.
	Pricing and other terms that are reasonably acceptable to Arena.

		
	4.
	Axovant shall not enter into a Third Party Manufacturing Agreement without submitting the proposed form of final Third Party Manufacturing Agreement to Arena and securing Arena's prior written approval, which approval shall not be unreasonably withheld or delayed. If Arena approves the Third Party Manufacturing Agreement, then the Parties shall amend Appendix B hereto to list such Third Party Manufacturing Agreement.

		
	5.
	With respect to each Third Party Manufacturing Agreement that is approved by Arena, the Parties further agree as follows:

		
	a.
	Axovant will ensure that all Manufacturing/Development Work conducted pursuant to such Third Party Manufacturing Agreement shall be done under a Development Plan that complies with the requirements of the Supply Agreement and includes a description of the Manufacturing/Development Work to be done by the Third Party.

		
	b.
	Axovant shall promptly notify Arena in writing of any Know-How and any Patents developed under the Third Party Manufacturing Agreement.

		
	c.
	Axovant hereby assigns to Arena or its Affiliate (as designated by Arena)  Axovant's entire right, title and interest in and to any and all Know-How and  Patents developed under the Third Party Manufacturing Agreement that are reasonably necessary for the development, manufacture or Commercialization of Compound or Product (including, for clarity, such Know-How and Patents that also relate solely to, or are specifically tailored for use in, the manufacture of Compound or Product). All such assigned Know-How and Patents shall be deemed to be Arena Know-How and Arena Patents, respectively.

		
	d.
	Axovant hereby grants to Arena or its Affiliate (as designated by Arena) an exclusive, worldwide, perpetual, royalty-free, fully paid-up sublicense  (with  the right to sublicense) to any Know-How or Patents assigned or licensed to Axovant under the Third Party Manufacturing Agreement  which are not assigned to Arena or its Affiliate pursuant to subsection 5.c., for any and all uses. In each case, such Know-How and Patents shall be deemed to be (i) Arena Know-How and Arena Patents, respectively, if they are reasonably necessary for the development, manufacture or Commercialization of Compound or Product; (ii) Program Know­ How and Program Patents, respectively, if they relate solely to, or are specifically tailored for use in, the manufacture of Compound or Product (and are not otherwise deemed Arena-Know or Arena Patents pursuant to (i) above); or

(iii) Manufacturing Know-How and Manufacturing Patents, if they do not fall within the scope of (i) or (ii) above.
		
	e.
	The Third Party may only deliver Compound and Product to Arena or to Arena' s designee, and Axovant will cause the Third Party to deliver Compound and Product to the location(s) and person(s) based on the instructions of Arena, which instructions may be modified from time to time.

		
	f.
	Upon receipt of notice from Arena that Arena elects assignment of a Third Party Manufacturing Agreement, Axovant shall immediately assign to Arena or its Affiliate (as designated by Arena) such agreement and take reasonable steps to assist in the transition of activities to Arena.

The Parties agree to promptly execute any documents, filings or further agreements to effect the above provisions, including relating to the assignment or sublicense of intellectual property.

Except as expressly set forth in this letter agreement, the Supply Agreement shall be unchanged and shall remain in full force and effect. Any breach or default of this side letter shall be considered a breach or default of the Supply Agreement. Any notice required or permitted under this letter agreement shall be given in accordance with Section 15.9 of the Supply Agreement.

Please indicate the agreement of Axovant to the terms of this letter agreement by returning the letter agreement countersigned below by an authorized representative of Axovant.

Very truly yours,

Arena Pharmaceuticals GmbH

By: /s/ Amit D. Munshi
Amit D. Munshi
Managing Director

By: /s/ Steven W. Spector
Steven W. Spector
Managing Director

Agreed:

Axovant Sciences GmbH

By: /s/ Marianne Romeo Dinsmore
Name: Marianne Romeo Dinsmore
Title: Managing Director

APPENDIX A

PROPOSED THIRD PARTY MANUFACTURERS

	
			
	Third Party
Name
	Proposed Manufacturing/Development Work
	Date Added to Appendix

	 
	 
	 

	 
	 
	 

APPENDIX B

APPROVED THIRD PARTY MANUFACTURING AGREEMENTS

	
				
	Agreement
Effective Date
	Agreement Counterparty
	Name of Agreement
	Date Added to AppendixEX-10.1

 Exhibit 10.1 

FIRST AMENDMENT 
 TO

 PURCHASE AND SALE AGREEMENT 

THIS FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT (herein called this “Amendment”) is made and entered into to be effective as of
the 27th day of October, 2017, by and between Nuvo Riverside, LLC, a Florida limited liability company (herein called “Seller”), and SST IV Acquisitions, LLC, a Delaware limited
liability company (herein called “Purchaser”). 
 W I T N E S S E T H: 

WHEREAS, Seller and Purchaser have heretofore entered into that certain Purchase and Sale Agreement dated on or about August 18, 2017
(herein called the “Contract”), respecting certain improved real property located at 10384 Riverside Drive, Palm Beach Gardens, Florida 33915, all as more particularly described in the Contract; and 

WHEREAS, Seller and Purchaser desire to modify the Contract, all as more particularly set forth below. 

NOW, THEREFORE, for and in consideration of the foregoing premises, and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereto do hereby agree as follows: 
 1. Approval Period. Section 4.1.1 of the Contract
is hereby modified to provide that the Approval Period shall expire at 5:00 p.m. Central Time on December 14, 2017. 
 2.
Miscellaneous. 
 (a) Seller and Purchaser hereby ratify the Contract in accordance with its terms, as modified hereby. 

(b) To the extent not otherwise defined herein, all capitalized terms used in this Amendment shall have the meanings ascribed to them in the
Contract. 
 (c) This Amendment shall be binding upon the parties hereto and their respective successors and permitted assigns. 

(d) This Amendment may be executed in a number of identical counterparts. If so executed, each of such counterparts shall be deemed an original
for all purposes, and such counterparts shall, collectively, constitute one agreement. 
 (e) For purposes of this Amendment, signatures
delivered by facsimile or electronic mail shall be as binding as originals upon the parties so signing and delivering. 

 (f) In the event of a conflict between the terms of this Amendment and the terms of the Contract,
the terms of this Amendment shall control. 
 (g) The captions and headings used in this Amendment are for convenience only and do not in any
way restrict, modify or amplify the terms of this Amendment or the Contract. 
 [Signature page to follow] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the day and year
first above written. 
  

			
	SELLER:
	
	 Nuvo Riverside, LLC,
 a Florida
limited liability company

		
	By:	 	 /s/ Gary Cardamone

	Name: Gary Cardamone
	Title:   Manager
	
	PURCHASER:
	
	 SST IV Acquisitions, LLC,
 a
Delaware limited liability company

		
	By:	 	 /s/ H. Michael Schwartz

	Name: H. Michael Schwartz
	Title:   Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]